ATP-competitive DNA gyrase and topoisomerase IV inhibitors as antibacterial agents

References

• Tommasi R, Brown DG, Walkup GK, et al. ESKAPEing the labyrinth of antibacterial discovery. Nat Rev Drug Discov. 2015;14(8):529–542.
   PubMed Web of Science ®Google Scholar
• Hiasha H. DNA topoisomerases as targets for antibacterial agents. Methods Mol Biol. 2018;1703:47–62.
   PubMedGoogle Scholar
• Tomasič T, Mašič LP. Prospects for developing new antibacterials targeting bacterial type IIA topoisomerases. Curr Top Med Chem. 2014;14(1):130–151.
   PubMed Web of Science ®Google Scholar
• Champoux JJ. DNA topoisomerases: structure, function, and mechanism. Annu Rev Biochem. 2001;70:369–413.
   PubMed Web of Science ®Google Scholar
• Azam MA, Thathan J, Jubie S. Dual targeting DNA gyrase B (GyrB) and topoisomerse IV (ParE) inhibitors: a review. Bioorg Chem. 2015;62:41–63.
   PubMed Web of Science ®Google Scholar
• Laponogov I, Sohi MK, Veselkov DA, et al. Structural insight into the quinolone-DNA cleavage complex of type IIA topoisomerases. Nat Struct Mol Biol. 2009;16(6):667–669.
   PubMed Web of Science ®Google Scholar
• Badshah SL, Ullah A. New developments in non-quinolone-based antibiotics for the inhibiton of bacterial gyrase and topoisomerase IV. Eur J Med Chem. 2018;152:393–400.
   PubMed Web of Science ®Google Scholar
• Bax BD, Chan PF, Eggleston DS, et al. Type IIA topoisomerase inhibition by a new class of antibacterial agents. Nature. 2010;466(7309):935–940.
   PubMed Web of Science ®Google Scholar
• Basarab GS, Kern GH, McNulty J, et al. Responding to the challenge of untreatable gonorrhea: ETX0914, a first-in-class agent with a distinct mechanism-of-action against bacterial Type II topoisomerases. Sci Rep. 2015;5:11827.
   PubMed Web of Science ®Google Scholar
• Wohlkonig A, Chan PF, Fosberry AP, et al. Structural basis of quinolone inhibition of type IIA topoisomerases and target-mediated resistance. Nat Struct Mol Biol. 2010;17(9):1152–1153.
   PubMed Web of Science ®Google Scholar
• Aldred KJ, McPherson SA, Turnbough CL Jr., et al. Topoisomerase IV-quinolone interactions are mediated through a water-metal ion bridge: mechanistic basis of quinolone resistance. Nucleic Acids Res. 2013;8:4628–4639.
   Google Scholar
• Owens B. Solithromycin rejection chills antibiotic sector. Nat Biotechnol. 2017;35(3):187–188.
   PubMed Web of Science ®Google Scholar
• New treatment for drug-resistant gonorrhea to enter phase 3 development [Internet]. Healio Infectious Disease News. 2017 Jul 8. [cited 2018 Nov 4]. Available from: https://www.healio.com/infectious-disease/antimicrobials/news/online/%7Bf01603b6-3d1d-4465-9d6f-1bb4f6cf36db%7D/new-treatment-for-drug-resistant-gonorrhea-to-enter-phase-3-development
   Google Scholar
• O’Riordan W, Tiffany C, Scangarella-Oman N, et al. Efficacy, safety, and tolerability of gepotidacin (GSK2140944) in the treatment of patients with suspected or confirmed gram-positive acute bacterial skin and skin structure infections. Antimicrob Agents Chemother. 2017;61:6.
   Web of Science ®Google Scholar
• Pharmacokinetic study of oral gepotidacin (GSK2140944) in subjects with uncomplicated urinary tract infection (acute cystitis) [Internet]. ClinicalTrials.gov. 2018 Jun 25. [cited 2018 Oct 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT03568942?term=gepotidacin&draw=2&rank=1
   Google Scholar
• Savage VJ, Charrier C, Salisbury AM, et al. Efficacy of a novel tricyclic topoisomerase inhibitor in a murine model of Neisseria gonorrhoeae infection. Antimicrob Agents Chemother. 2016;60(9):5592–5594.
   PubMed Web of Science ®Google Scholar
• Savage VJ, Charrier C, Salisbury AM, et al. Biological profiling of novel tricyclic inhibitors of bacterial DNA gyrase and topoisomerase IV. J Antimicrob Chemother. 2016;71(7):1905–1913.
   PubMed Web of Science ®Google Scholar
• Oblak M, Kotnik M, Solmajer T. Discovery and development of ATPase inhibitors of DNA gyrase as antibacterial agents. Curr Med Chem. 2007;14(19):2033–2047.
   PubMed Web of Science ®Google Scholar
• Lewis RJ, Singh OMP, Smith CV, et al. The nature of inhibition of DNA gyrase by the coumarins and the cyclothialidines revealed by X-ray crystallography. EMBO J. 1996;15(6):1412–1420.
   PubMed Web of Science ®Google Scholar
• Bisacchi GS, Manchester JI. A new-class antibacterial-almost. Lessons in drug discovery and development: a critical analysis of more than 50 years of effort toward ATPase inhibitors of DNA gyrase and topoisomerase IV. ACS Infect Dis. 2015;1(1):4–41.
   PubMed Web of Science ®Google Scholar
• Barančoková M, Kikelj D, Ilaš J. Recent progress in the discovery and development of DNA gyrase B inhibitors. Future Med Chem. 2018;10(10):1207–1227.
   PubMed Web of Science ®Google Scholar
• Uria-Nickelsen M, Neckermann G, Sriram S, et al. Novel topoisomerase inhibitors: microbiological characterisation and in vivo efficacy of pyrimidines. Int J Antimicrob Agents. 2013;41(4):363–371.
   PubMed Web of Science ®Google Scholar
• Yager K, Chu S, Appelt A, et al. Quorex Pharmaceuticals, Pfizer Inc. Gyrase inhibitors. US20050054697A1. 2005.
   Google Scholar
• Ronkin SM, Badia M, Bellon S, et al. Discovery of pyrazolthiazoles as novel and potent inhibitors of bacterial gyrase. Bioorg Med Chem Lett. 2010;20(9):2828–2831.
   PubMed Web of Science ®Google Scholar
• Sciotti RJ, Starr JT, Richardson C, et al. Imidazopyridine and imidazopyrimidine derivatives as antibacterial agents. WO2005089763A1. 2005.
   Google Scholar
• Butler DCD, Chen H, Hedge VR, et al. Warner-Lambert Co. Triazolopyridine derivatives as antibacterial agents. WO2006038116A2. 2006.
   Google Scholar
• Basarab GS, Manchester JI, Bist S, et al. Fragment-to-hit-to-lead discovery of a novel pyridylurea scaffold of ATP competitive dual targeting type II topoisomerase inhibiting antibacterial agents. J Med Chem. 2013;56(21):8712–8735.
   PubMed Web of Science ®Google Scholar
• Charifson PS, Grillot AL, Grossman TH, et al. Novel dual-targeting benzimidazole urea inhibitors of DNA gyrase and topoisomerase IV possessing potent antibacterial activity: intelligent design and evolution through the judicious use of structure-guided design and structure-activity relationships. J Med Chem. 2008;51(17):5243–5263.
   PubMed Web of Science ®Google Scholar
• Axford LC, Agarwal PK, Anderson KH, et al. Design, synthesis and biological evaluation of alpha-substituted isonipecotic acid benzothiazole analogues as potent bacterial type II topoisomerase inhibitors. Bioorg Med Chem Lett. 2013;23(24):6598–6603.
   PubMed Web of Science ®Google Scholar
• Mesleh MF, Cross JB, Zhang J, et al. Fragment-based discovery of DNA gyrase inhibitors targeting the ATPase subunit of GyrB. Bioorg Med Chem Lett. 2016;26(4):1314–1318.
   PubMed Web of Science ®Google Scholar
• AZD 5099 [Internet]. Adis Insight. 2012 Aug 6. [cited 2018 Nov 4]. Available from: https://adisinsight.springer.com/drugs/800034406
   Google Scholar
• Charifson P, Deininger D, Drumm J, et al. Vertex Pharmaceuticals, Inc. Gyrase inhibitors and uses thereof. US20130030004A1. 2013.
   Google Scholar
• Lunniss CJ, Palmer JT, Pitt GRW, et al. Biota Europe Ltd. Antibacterial compounds. WO2013138860A1. 2013.
   Google Scholar
• Creighton C, Tari L, Chen Z, et al. Trius Therapeutics, Inc. Gyrase inhibitors. WO2011032050A2. 2011.
   Google Scholar
• Bensen D, Finn J, Lee SJ, et al. Trius Therapeutics, Inc. Tricyclic gyrase inhibitors. WO2012125746A1. 2012.
   Google Scholar
• Soneda T, Takeshita H, Kagoshima Y, et al. Daiichi Sankyo Company, Ltd. Imidazole carbonyl compound. WO2009084614A1. 2009.
   Google Scholar
• Khera MK, Mathur T, Sattigeri JA, et al. Daiichi Sankyo Company Ltd. Hydroxyalkyl thiadiazole derivatives. WO2017056012A1. 2017.
   Google Scholar
• Grillot AL, Charifson PS, Stamos D, et al. Vertex Pharmaceuticals, Inc. Bacterial gyrase inhibitors and uses thereof. WO2002060879A2. 2002.
   Google Scholar
• Grossman TH, Bartels DJ, Mullin S, et al. Dual targeting of GyrB and ParE by a novel aminobenzimidazole class of antibacterial compounds. Antimicrob Agents Chemother. 2007;51(2):657–666.
   PubMed Web of Science ®Google Scholar
• Finn J. Evaluation of WO2012177707 and WO2012097269: vertex’s phosphate prodrugs of gyrase and topoisomerase antibacterial agents. Expert Opin Ther Pat. 2013;23(9):1233–1237.
   PubMed Web of Science ®Google Scholar
• Grillot AL, Le Tiran A, Shannon D, et al. Second-generation antibacterial benzimidazole ureas: discovery of a preclinical candidate with reduced metabolic liability. J Med Chem. 2014;57(21):8792–8816.
   PubMed Web of Science ®Google Scholar
• Le Tiran A, Grillot AL, Charifson PS, et al. Vertex Pharmaceuticals, Inc. Pyrimidine gyrase and topoisomerase IV inhibitors. WO2012097269A1. 2012.
   Google Scholar
• Bennani YL, Charifson PS, Grillot AL, et al. Vertex Pharmaceuticals, Inc. Phosphate esters of gyrase and topoisomerase inhibitors. WO2012177707A1. 2012.
   Google Scholar
• Shannon D, Luisi B, Krawiec M, et al. Vertex Pharmaceuticals, Inc. Solid forms of gyrase inhibitor (R)-1-ethyl-3-[6-fluoro-5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-7-(tetrahydrofuran-2-yl)-1H-benzimidazol-2-yl]urea. US20120184564A1. 2012.
   Google Scholar
• Shannon D, Luisi B, Liao Y, et al. Vertex Pharmaceuticals, Inc. Solid forms of gyrase inhibitor (R)-1-ethyl-3-[5-[2-(1-hydroxy-methyl-ethyl)pyrimidin-5-yl]-7-(tetrahydrofuran-2-yl)-1H-benzimidazol-2-yl]urea. US20120184741A1. 2012.
   Google Scholar
• O’Dowd H, Macikenas D, Song B; Vertex Pharmaceuticals, Inc. Solid forms of (R)-2-(5-(2-(3-ethylureido)-6-fluoro-7-(tetrahydrofuran-2-yl)-1H-benzo[d]imidazol-5-yl)pyrimidin-2-yl)propan-2-yl dihidrigen phosphate and salts thereof. US20140031318A1. 2014.
   Google Scholar
• Shannon D, Wang T, Giroux S. Vertex Pharmaceuticals, Inc. Process of making gyrase and topoisomerase IV inhibitors. US20120184742A1. 2012.
   Google Scholar
• O’Dowd H, Shannon DE, Chandupatla KR, et al. Discovery and characterization of a water-soluble prodrug of a dual inhibitor of bacterial DNA gyrase and topoisomerase IV. ACS Med Chem Lett. 2015;6(7):822–826.
   PubMed Web of Science ®Google Scholar
• Spero therapeutics receives grant from national institutes of health to explore novel treatment combinations for tuberculosis [Internet]. Spero Therapeutics. 2017 May 4. [cited 2018 Oct 19]. Available from: https://investors.sperotherapeutics.com/news-releases/news-release-details/spero-therapeutics-receives-grant-national-institutes-health
   Google Scholar
• SUNDAY - 43/SUNDAY - 43 - Efficacy of SPR720 and SPR750 gyrase inhibitors in a mouse Mycobacterium tuberculosis infection model [Internet]. ASM Microbe 2017. 2017 Jun 4. [cited 2018 Oct 19]. Available from: http://www.abstractsonline.com/pp8/#!/4358/presentation/6167
   Google Scholar
• Locher CP, Jones SM, Hanzelka BL, et al. A novel inhibitor of gyrase B is a potent drug candidate for treatment of tuberculosis and nontuberculosis mycobacterial infections. Antimicrob Agents Chemother. 2015;59(3):1455–1465.
   PubMed Web of Science ®Google Scholar
• Programs designed to address unmet needs in infectious diseases [Internet]. Spero Therapeutics. 2018. [cited 2018 Oct 20]. Available from: https://sperotherapeutics.com/pipeline/
   Google Scholar
• SPR 720 [Internet]. Adis Insight. 2018. [cited 2018 Oct 19]. Available from: https://adisinsight.springer.com/drugs/800049042
   Google Scholar
• Palmer JT, Lunniss CJ, Offermann DA, et al. Biota Europe Ltd. Bacteria topoisomerase II inhibiting 2-ethylcarbamoylamino-1,3-benzothiazol-5-yls. WO2012045124A1. 2012.
   Google Scholar
• Stokes NR, Thomaides-Brears HB, Barker S, et al. Biological evaluation of benzothiazole ethyl urea inhibitors of bacterial type II topoisomerases. Antimicrob Agents Chemother. 2013;57(12):5977–5986.
   PubMed Web of Science ®Google Scholar
• Biota pharmaceuticals sells antibiotic program to spero therapeutics [Internet]. Genetic Engineering & Biotechnology News. 2016 Mar 17. [cited 2018 Oct 20]. Available from: https://www.genengnews.com/gen-news-highlights/biota-pharmaceuticals-sells-antibiotic-program-to-spero-therapeutics/81252487/
   Google Scholar
• Lunniss CJ, Palmer JT, Pitt GRW, et al. Spero Gyrase, Inc. Antibacterial compounds. US20170260178A1. 2017.
   Google Scholar
• Merck in $8.4 billion deal for cubist, big maker of antibiotics [Internet]. Dealbook. 2014 Dec 8. [cited 2018 Nov 4] Available from: https://dealbook.nytimes.com/2014/12/08/merck-agrees-to-acquire-drug-maker-cubist-for-9-5-billion/
   Google Scholar
• Creighton CJ, Tari LW, Chen Z, et al. Merck Sharp & Dohme Corp. Gyrase inhibitors. US9481675B2. 2016.
   Google Scholar
• Creighton CJ, Tari LW, Chen Z, et al. Merck Sharp & Dohme Corp. Gyrase inhibitors. US20170037059A1. 2017.
   Google Scholar
• Bensen D, Borchardt A, Chen Z, et al. Trius Therapeutics, Inc., Lawrence Livermore National Security, LLC. Tricyclic gyrase inhibitors for use as antibacterial agents. WO2014043272A1. 2014.
   Google Scholar
• Finn J, Tari LW, Chen Z, et al. Trius Therapeutics, Inc. Tricyclic gyrase inhibitors. WO2015038661A1. 2015.
   Google Scholar
• Bensen D, Chen Z, Finn J, et al. Merck Sharp & Dohme Corp. Tricyclic gyrase inhibitors. US20170369498A1. 2017.
   Google Scholar
• Dey F, Hu Y, Liu Y, et al. Hoffmann-La Roche, Inc. Novel pyrido[2,3-b]indole compounds for the treatment and prophylaxis of bacterial infections. WO2018178041A1. 2018.
   Google Scholar
• Abdel-Magid AF. Inhibitors of DNA gyrase-GyrB subunit and/or topoisomerase IV-ParE subunit may treat infectious diseases caused by antibiotic-resistant bacteria. ACS Med Chem Lett. 2017;8(6):592–594.
   PubMedGoogle Scholar
• Barman TK, Kumar M, Mathur T, et al. In vitro and in vivo activities of DS-2969b, a novel GyrB inhibitor, and its water-soluble prodrug, DS11960558, against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2018;62(6).
   Web of Science ®Google Scholar
• Khera MK, Dumbre NC, Khan P. Daiichi Sankyo Company, Ltd. N-Phosphonoxymethyl prodrugs of hydroxyalkyl thiadiazole derivatives. WO2018169092A1. 2018.
   Google Scholar
• Mathur T, Barman TK, Kumar M, et al. In vitro and in vivo activities of DS-2969b, a novel GyrB inhibitor, against Clostridium difficile. Antimicrob Agents Chemother. 2018;62(4).
   Web of Science ®Google Scholar
• Vandell AG, Inoue S, Dennie J, et al. Phase 1 study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple oral doses of DS-2969b, a novel GyrB inhibitor, in healthy subjects. Antimicrob Agents Chemother. 2018;62(5).
   PubMed Web of Science ®Google Scholar
• Morrissey I, De Piano C, Magnet S, et al. Activity of DS-2969b, a novel GyrB inhibitor, against recent clinical isolates of Clostridium difficile from Europe. [cited 2018 Oct 18]. Available from: https://www.ihma.com/app/uploads/SUNDAY-258-IHMA.pdf
   Google Scholar
• European Medicines Agency. [Internet]. 2017 Mar 15. [cited 2019 Jan 18] Available from: https://www.ema.europa.eu/documents/referral/quinolone-fluoroquinolone-article-31-referral-annex-i_en.pdf
   Google Scholar
• Richter MF, Drown BS, Riley AP, et al. Predictive compound accumulation rules yield a broad-spectrum antibiotic. Nature. 2017;545(7654):299–304.
   PubMed Web of Science ®Google Scholar
• Richter MF, Hergenrother PJ. The challenge of converting Gram-positive-only compounds into broad-spectrum antibiotics. Ann N Y Acad Sci. 2018;1435(1):18–38.
   PubMed Web of Science ®Google Scholar